PCRX logo

PACIRA BIOSCIENCES INC

PCRXNASDAQ
🏆 #2145 by market capUS Equity
$36.38—
Last available close · quote unavailable
🔔
Track PCRX
Get earnings, price moves & breaking news on Telegram
Track
24h—
7d▲ 0.1%
14d▲ 0.1%
30d▲ 41.7%
ytd▲ 40.7%
1y▲ 73.4%
🏦Market Cap
$1.45B
Small Cap
📈Revenue Growth (YoY)
3.6%
Slowing
📊Gross Margin
79.2%
High
💵FCF Margin
24.1%
Strong
⚖️P/S Ratio
1.9x
Cheap
Otter Score
88
Excellent

Trading Snapshot

Day Range
—
52-Week Range
$18.80 – $36.67
Volume (shares)
—
Avg Volume (shares)
—
Shares Outstanding
39.9M
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
$726M
Last Q Revenue
$192M
P/E Ratio
103.4
P/S Ratio
1.9x
EPS (TTM)
$0.37
Dividend Yield
0.00%
Dilution (1yr)
−12.3%
PCRX logo

PACIRA BIOSCIENCES INC

PCRX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$726M▲ +3.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
79.4%▲ +4.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$33M▼ −145.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$137M▼ −23.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
43.0M▼ −12.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$296M▲ +$66M YoY
StockOtter · stockotter.space

About PACIRA BIOSCIENCES INC

Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Excellent
88/100
Analyst data unavailable.

Latest News & Updates

News unavailable.